Inovio Pharmaceuticals (INO) : Traders are bullish on Inovio Pharmaceuticals (INO) as it has outperformed the S&P 500 by a wide margin of 10.05% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 7.88%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 8.45% in the last 1 week, and is up 7.82% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 2.31% and the 50-Day Moving Average is 0.98%.The 200 Day SMA reached 10.29% Inovio Pharmaceuticals, Inc. has dropped 11.75% during the last 3-month period . Year-to-Date the stock performance stands at 37.5%.
Inovio Pharmaceuticals (INO) stock is expected to deviate a maximum of $7.8 from the average target price of $19.75 for the short term period. 4 Street Experts have initiated coverage on the stock with the most promising target being $31 and the most muted being $13.
For the current week, the company shares have a recommendation consensus of Buy. Inovio Pharmaceuticals (NASDAQ:INO): stock was range-bound between the intraday low of $9.16 and the intraday high of $9.53 after having opened at $9.42 on Fridays session. The stock finally closed in the red at $9.42, a loss of -2.53%. The stock remained in the red for the whole trading day. The total traded volume was 1,488,491 shares. The stock failed to cross $9.53 in Fridays trading. The stocks closing price on Thursday was $9.24.
Inovio Pharmaceuticals, Inc. (Inovio) is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. As of December 31, 2014, Inovio had completed clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), HIV, influenza and Ebola. With its immunotherapy platform consisting of SynCon products, as well as its CELLECTRA electroporation delivery technology, Inovio has developed a pipeline of pre-clinical and clinical stage products that have generated in vivo (in the body) immune responses. Inovios immunotherapies are delivered into cells of the body into a small local area of tissue using its electroporation (EP) DNA delivery technology.